Radiolabeled antibodies in renal cell carcinoma
Open Access
- 1 January 2007
- journal article
- review article
- Published by E-MED LTD in Cancer Imaging
- Vol. 7 (1), 179-188
- https://doi.org/10.1102/1470-7330.2007.0025
Abstract
Renal cell carcinoma (RCC) is a radio- and chemotherapy resistant tumor, which has a very high morbidity and mortality when metastasized. The current treatment options demonstrate limited efficacy and severe side-effects. Therefore, there is a need for new therapeutic strategies for RCC. As for other malignancies, monoclonal antibodies (mAbs) targeting tumor-associated antigens have been developed for RCC. One of these, mAb G250, targets the MN/CAIX/G250 antigen, which is ubiquitously expressed in clear cell RCC (ccRCC). ccRCC is the most common form of RCC with a prevalence of 80%. Expression of G250 in normal tissue is restricted to the gastrointestinal mucosa and related structures, thereby making it a suitable candidate for targeting ccRCC. In several clinical studies the efficient accumulation of mAb G250 in ccRCC has been demonstrated, resulting in high contrast images. G250-imaging could prove to be a valuable tool in diagnosing metastases in patients with a G250-antigen positive primary tumor and/or in the differential diagnosis of suspect kidney lesions. Furthermore, the therapeutic efficacy of radiolabeled G250 has been investigated in a series of studies. Thus far, most efforts have been devoted to G250 labeled with high doses of 131I. Other radionuclides which may enhance the therapeutic index of this radiolabeled mAb are currently under investigation. In our institution, an activity dose escalation study is currently ongoing to investigate the therapeutic potential of 177Lu-labeled G250 in metastatic ccRCC patients. In this review, the current status of the diagnostic and therapeutic properties of radiolabeled antibodies in RCC is described.Keywords
This publication has 87 references indexed in Scilit:
- Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- Pretargeted radioimmunotherapy of cancer: progress step by step.2003
- Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicityCancer Immunology, Immunotherapy, 2002
- Gastrin Releasing Peptide-Preferring Bombesin Receptors Mediate Growth of Human Renal Cell CarcinomaJournal of the American Society of Nephrology, 2000
- Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodiesInternational Journal of Cancer, 1998
- Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tractsGastroenterology, 1997
- Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.1996
- Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells.1992
- Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide.1987
- LOCALIZATION OF HUMAN RENAL-CELL CARCINOMA XENOGRAFTS WITH A TUMOR-PREFERENTIAL MONOCLONAL-ANTIBODY1985